The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

Type
Public
HQ
Paris, FR
Founded
1999
Size (employees)
203 (est)
Cellectis was founded in 1999 and is headquartered in Paris, FR
Report incorrect company information

Cellectis Office Locations

Cellectis has offices in Paris and New York
Paris, FR (HQ)
8 Rue de la Croix Jarry
New York, US
430 E 29th St
Show all (2)
Report incorrect company information

Cellectis Financials and Metrics

Cellectis Financials

Market capitalization (31-Oct-2017)

1.1 b

Closing share price (31-Oct-2017)

28.9
Cellectis's current market capitalization is €1.1 b.
Show all financial metrics
Report incorrect company information

Cellectis News and Updates

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Market (Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Cellectis) Consumption, Recent Developments, and Comprehensive Forecast

ReportsWeb.com added “Global CRISPR Market Size Status and Forecast 2022” to its vast collection of research Database. The report classifies the global CRISPR Market in a precise manner to offer detailed insights into the aspects responsible for augmenting as well as restraining market growth. Poste…
Report incorrect company information